Christoph Westphal Leaving GlaxoSmithKline’s SR One to Focus on Longwood Founders Fund
Published: Apr 04, 2011
Xconomy -- Christoph Westphal, the Boston-based biotech mover/shaker, is leaving GlaxoSmithKline (NYSE: GSK) later this year to focus on Longwood Founders Fund and other business interests, according to a press release this morning. Westphal is currently president of SR One, GSK’s venture capital arm. London-based GSK is also an investor in Longwood Founders Fund, the relatively new VC fund started by Westphal, Michelle Dipp, and Rich Aldrich.